KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Accumulated Expenses: 2011-2024

Historic Accumulated Expenses for Supernus Pharmaceuticals (SUPN) over the last 13 years, with Dec 2024 value amounting to $168.7 million.

  • Supernus Pharmaceuticals' Accumulated Expenses rose 9.07% to $184.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $184.5 million, marking a year-over-year increase of 9.07%. This contributed to the annual value of $168.7 million for FY2024, which is 9.35% up from last year.
  • Supernus Pharmaceuticals' Accumulated Expenses amounted to $168.7 million in FY2024, which was up 9.35% from $154.3 million recorded in FY2023.
  • Supernus Pharmaceuticals' 5-year Accumulated Expenses high stood at $168.7 million for FY2024, and its period low was $126.2 million during FY2020.
  • Its 3-year average for Accumulated Expenses is $158.2 million, with a median of $154.3 million in 2023.
  • Data for Supernus Pharmaceuticals' Accumulated Expenses shows a peak YoY grew of 17.25% (in 2020) over the last 5 years.
  • Yearly analysis of 5 years shows Supernus Pharmaceuticals' Accumulated Expenses stood at $126.2 million in 2020, then increased by 5.18% to $132.7 million in 2021, then grew by 14.27% to $151.7 million in 2022, then rose by 1.72% to $154.3 million in 2023, then grew by 9.35% to $168.7 million in 2024.